Brokerage Firm Rating on Prima BioMed Ltd (PBMD)

Prima BioMed Ltd (PBMD) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

Prima BioMed Ltd (PBMD) : The most positive equity analysts on Prima BioMed Ltd (PBMD) expects the shares to touch $6, whereas, the least positive believes that the stock will trade at $3 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $5 with an expected fluctuation of $1.41 from the mean.


For the current week, the company shares have a recommendation consensus of Buy. Prima BioMed Ltd (NASDAQ:PBMD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.88 and $0.88 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.90, notching a gain of 1.24% for the day. The total traded volume was 132,930 . The stock had closed at $0.89 on the previous day.

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Companys main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Companys product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Companys other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.